Stocks and Investing Stocks and Investing
Tue, March 12, 2024

Sumant Kulkarni Maintained (ACAD) at Strong Buy with Decreased Target to $33 on, Mar 12th, 2024


Published on 2024-10-28 09:37:57 - WOPRAI, Sumant Kulkarni
  Print publication without navigation


Sumant Kulkarni of Canaccord Genuity, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Strong Buy with Decreased Target from $40 to $33 on, Mar 12th, 2024.

Sumant has made no other calls on ACAD in the last 4 months.



There are 5 other peers that have a rating on ACAD. Out of the 5 peers that are also analyzing ACAD, 2 agree with Sumant's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $27 on, Monday, December 18th, 2023
  • Neena Bitritto-Garg of "Deutsche Bank" Downgraded from Strong Buy to Hold and Held Target at $25 on, Thursday, December 14th, 2023


These are the ratings of the 3 analyists that currently disagree with Sumant


  • Tessa Romero of "JP Morgan" Maintained at Buy with Decreased Target to $29 on, Friday, March 1st, 2024
  • Joseph Stringer of "Needham" Upgraded from Hold to Strong Buy and Held Target at $37 on, Wednesday, January 24th, 2024
  • Jeffrey Hung of "Morgan Stanley" Upgraded from Hold to Buy and Increased Target to $40 on, Tuesday, December 19th, 2023
Contributing Sources